Tiotropium improved asthma symptoms and increased time to first exacerbation in patients with moderate-to-severe asthma. Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020
The relationship of gastroesophageal reflux with asthma quality of life and asthma control test in asthmatic patients Source: Annual Congress 2011 - Asthma: risk factors and comorbidities Year: 2011
Dupilumab improves asthma control and quality of life in children with uncontrolled persistent asthma Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches Year: 2021
Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005
Formoterol Turbuhaler® reduces the need for relief medication in children with mild to moderate asthma and improves quality of life Source: Eur Respir J 2001; 18: Suppl. 33, 291s Year: 2001
Effect of BMI on asthma control, asthma severity and quality of life in adult patients with asthma Source: Annual Congress 2011 - Asthma: improving diagnosis and management for reaching better control Year: 2011
Pretreatment with inhaled procaterol improves symptoms of dyspnea and quality of life in patients with severe COPD Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012
Omalizumab improves asthma-specific quality of life in patients with severe allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001
Omalizumab significantly improves quality of life in patients with severe persistent allergic asthma: a pooled analysis Source: Eur Respir J 2005; 26: Suppl. 49, 49s Year: 2005
Budesonide/formoterol for maintenance and relief in adolescents with asthma: fewer exacerbations and improved asthma control Source: Eur Respir J 2004; 24: Suppl. 48, 164s Year: 2004
Adding omalizumab to high-dose ICS and LABA significantly improves quality of life in patients with severe persistent allergic asthma Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006
Tiotropium add-on therapy reduces seasonal peaks of asthma worsening in adults with symptomatic severe asthma Source: Eur Respir J, 55 (1) 1900964; 10.1183/13993003.00964-2019 Year: 2020
Effects of adding salmeterol to inhaled corticosteroids on lung function and quality of life in patients with mild persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 499s Year: 2006
Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017
Reduction in percent of days with asthma symptoms and activity limitation in young asthmatic children treated with Montelukast Source: Eur Respir J 2001; 18: Suppl. 33, 290s Year: 2001
Improvement of control and quality of life in severe allergic asthmatics patients treated with omalizumab Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008
Omalizumab (Xolair®) reduces exacerbations in patients with moderate-to-severe persistent allergic asthma independent of former smoking status Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008
Improving effect of fudosteine on sputum symptoms and health-related quality of life of patients with bronchial asthma Source: Eur Respir J 2006; 28: Suppl. 50, 115s Year: 2006
Intranasal budesonide improves quality of life in patient with COPD and chronic nasal symptoms Source: International Congress 2016 – COPD diagnosis and management Year: 2016
Effect of dupilumab on patient-reported sleep outcomes in patients with severe asthma Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021